Akeso and Sino Bio Approved to Launch PD-1 in China
publication date: Aug 6, 2021
Akeso and Sino Bio were approved to launch their partnered anti-PD-1 injection in China for classic Hodgkin's lymphoma. According to the companies, Penpulimab is currently the only PD-1 that applies IgG1 subtype and is modified by Fc segment, giving it a lower antigen binding dissociation rate and a unique binding epitope. As a result, Penpulimab offers effective and continuous blocking of PD-1/PD-L1 binding. This enhances the immunotherapeutic efficacy and reduces immune-related adverse reactions, the companies believe. More details....
Stock Symbols: (HK: 9926) (HK: 1177)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.